| Citation: |
MA Shishi, DAI Yuran, CHEN Xiaopin. Research Progress on Postoperative Adjuvant Therapy for Completely Resected Stage ⅠB Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(3): 303-308. DOI: 10.3971/j.issn.1000-8578.2023.22.0933
|
Lung cancer is considered as the leading cause of cancer-related mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about 85% of primary lung cancer. Owing to the improved utilization of medical technological level and the popularization of health examinations, the detection rate of early-stage NSCLC is gradually increasing. The main treatment modalities for early-stage NSCLC are surgical resection and adjuvant chemotherapy. Platinum-based chemotherapy is recommended as the standard postoperative adjuvant treatment for patients with completely resected stageⅡ-ⅢA NSCLC. However, adjuvant therapy remains a controversial option in stageⅠB NSCLC. This review focuses on postoperative adjuvant therapy such as adjuvant chemotherapy, targeted therapy, and immunotherapy for completely resected stageⅠB NSCLC. Moreover, the biomarkers and prognostic factors of high-risk patients are discussed.
Competing interests: The authors declare that they have no competing interests.
| [1] |
中国临床肿瘤学会. 非小细胞肺癌诊疗指南2021[M]. 北京: 人民卫生出版社, 2021: 71-73.
Chinese Society of Clinical Oncology Guidelines Working Committee Organization. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosisand treatmentof Non-Small Cell Lung Cancer-2021[M]. Beijing: People's Health Publishing House, 2021: 71-73.
|
| [2] |
Detterbeck FC, Boffa DJ, Kim AW, et al. The Eighth Edition Lung Cancer Stage Classification[J]. Chest, 2017, 151(1): 193-203. doi: 10.1016/j.chest.2016.10.010
|
| [3] |
Wang J, Wu N, Lv C, et al. Should patients with stage IB non-small cell lung cancer receive adjuvant chemotherapy?A comparison of survival between the 8th and 7th editions of the AJCC TNM staging system for stageⅠB patients[J]. J Cancer Res Clin Oncol, 2019, 145(2): 463-469. doi: 10.1007/s00432-018-2801-7
|
| [4] |
Postmus PE, Kerr KM, Oudkerk M, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28(suppl_4): iv1-iv21.
|
| [5] |
Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 With the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups[J]. J Clin Oncol, 2008, 26(31): 5043-5051. doi: 10.1200/JCO.2008.16.4855
|
| [6] |
Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2022, 20(5): 497-530. doi: 10.6004/jnccn.2022.0025
|
| [7] |
中国抗癌协会肺癌专业委员会, 中华医学会肿瘤学分会肺癌学组, 中国胸部肿瘤研究协作组. Ⅰ~ⅢB期非小细胞肺癌完全切除术后辅助治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(16): 1132-1142. doi: 10.3760/cma.j.cn112137-20210210-00406
ChineseAnti-Cancer Association Lung Cancer Professional Committee, Chinese Medical Association OncologyBranch Lung Cancer Group, China Thoracic Cancer Research Collaborative Group. Guidelinesfor adjuvant therapy after complete resection of stage Ⅰ-ⅢB non-small cell lung cancer (2021 edition)[J]. Zhonghua Yi Xue Za Zhi, 2021, 101(16): 1132-1142. doi: 10.3760/cma.j.cn112137-20210210-00406
|
| [8] |
NSCLC Meta-analyses Collaborative Group, Arriagada R, Auperin A, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data[J]. Lancet, 2010, 375(9722): 1267-1277. doi: 10.1016/S0140-6736(10)60059-1
|
| [9] |
Wang X, Chen D, Wen J, et al. Benefit of adjuvant chemotherapy for patients with stageⅠB non-small cell lung cancer: a systematic review and meta-analysis[J]. Ann Transl Med, 2021, 9(18): 1430. doi: 10.21037/atm-21-4001
|
| [10] |
Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage ⅠB nonsmall cell lung cancer: Long-term survival in a randomized study[J]. Int J Cancer, 2006, 119(4): 955-960. doi: 10.1002/ijc.21933
|
| [11] |
Nakagawa K, Tada H, Akashi A, et al. Randomised study of adjuvant chemotherapy for completely resected p-stage Ⅰ-ⅢA non-small cell lung cancer[J]. Br J Cancer, 2006, 95(7): 817-821. doi: 10.1038/sj.bjc.6603336
|
| [12] |
Butts CA, Ding K, Seymour L, et al. Randomized phaseⅢtrial of vinorelbine plus cisplatin compared with observation in completely resected stage ⅠB and Ⅱ non-small-cell lung cancer: updated survival analysis of JBR-10[J]. J Clin Oncol, 2010, 28(1): 29-34. doi: 10.1200/JCO.2009.24.0333
|
| [13] |
Douillard JY, Rosell R, de Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stageⅠB-ⅢA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association[ANITA]): a randomised controlled trial[J]. Lancet Oncol, 2006, 7(9): 719-727. doi: 10.1016/S1470-2045(06)70804-X
|
| [14] |
Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group[J]. J Clin Oncol, 2008, 26(21): 3552-3559. doi: 10.1200/JCO.2007.13.9030
|
| [15] |
Jiang L, Liang W, Shen J, et al. The impact of visceral pleural invasion in node-negative non-small cell lung cancer: a systematic review and meta-analysis[J]. Chest, 2015, 148(4): 903-911. doi: 10.1378/chest.14-2765
|
| [16] |
Wu YL, John T, Grohe C, et al. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC[J]. J Thorac Oncol, 2022, 17(3): 423-433. doi: 10.1016/j.jtho.2021.10.014
|
| [17] |
Pennell NA, Neal JW, Chaft JE, et al. SELECT: A PhaseⅡ Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2019, 37(2): 97-104. doi: 10.1200/JCO.18.00131
|
| [18] |
Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib Versus Placebo in Patients With StageⅠB-ⅢA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase Ⅲ Trial[J]. J Clin Oncol, 2015, 33(34): 4007-4014. doi: 10.1200/JCO.2015.61.8918
|
| [19] |
Goss GD, O'callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study[J]. J Clin Oncol, 2013, 31(27): 3320-3326. doi: 10.1200/JCO.2013.51.1816
|
| [20] |
Hsu PC, Jablons DM, Yang CT, et al. Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)[J]. Int J Mol Sci, 2019, 20(15): 3821. doi: 10.3390/ijms20153821
|
| [21] |
Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage ⅠB-ⅢA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet, 2021, 398(10308): 1344-1357. doi: 10.1016/S0140-6736(21)02098-5
|
| [22] |
Lin MW, Wu CT, Shih JY, et al. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension[J]. J Surg Oncol, 2014, 110(2): 99-106. doi: 10.1002/jso.23628
|
| [23] |
Gong L, He R, Xu Y, et al. Neoantigen load as a prognostic and predictive marker for stage Ⅱ/Ⅲ non-small cell lung cancer in Chinese patients[J]. Thorac Cancer, 2021, 12(15): 2170-2181. doi: 10.1111/1759-7714.14046
|
| [24] |
Kamal NS, Soria JC, Mendiboure J, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer[J]. Clin Cancer Res, 2010, 16(4): 1206-1215. doi: 10.1158/1078-0432.CCR-09-2204
|
| [25] |
Machado-Rugolo J, Fabro AT, Ascheri D, et al. Usefulness of complementary next-generation sequencing and quantitative immunohistochemistry panels for predicting brain metastases and selecting treatment outcomes of non-small cell lung cancer[J]. Hum Pathol, 2019, 83: 177-191. doi: 10.1016/j.humpath.2018.08.026
|
| [26] |
Tsakonas G, Botling J, Micke P, et al. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer[J]. Lung Cancer, 2019, 133: 69-74. doi: 10.1016/j.lungcan.2019.04.028
|
| [27] |
Mony JT, Schuchert MJ. Prognostic Implications of Heterogeneity in Intra-tumoral Immune Composition for Recurrence in Early Stage Lung Cancer[J]. Front Immunol, 2018, 9: 2298. doi: 10.3389/fimmu.2018.02298
|
| [28] |
Peng M, Huang Q, Yin W, et al. Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer[J]. Front Oncol, 2020, 10: 561598. doi: 10.3389/fonc.2020.561598
|
| [29] |
de Miguel-Pérez D, Bayarri-Lara CI, Ortega FG, et al. Post-Surgery Circulating Tumor Cells and AXL Overexpression as New Poor Prognostic Biomarkers in Resected Lung Adenocarcinoma[J]. Cancers (Basel), 2019, 11(11): 1750. doi: 10.3390/cancers11111750
|
| [30] |
Kim IA, Hur JY, Kim HJ, et al. Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma[J]. Ann Surg Oncol, 2021, 28(7): 3983-3993. doi: 10.1245/s10434-020-09276-x
|
| [31] |
Lim JU, Yeo CD. Update on adjuvant therapy in completely resected NSCLC patients[J]. Thorac Cancer, 2022, 13(3): 277-283. doi: 10.1111/1759-7714.14277
|
| [32] |
Kratz JR, Haro GJ, Cook NR, et al. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging[J]. J Thorac Oncol, 2019, 14(7): 1223-1232. doi: 10.1016/j.jtho.2019.03.015
|
| [33] |
Woodard GA, Wang SX, Kratz JR, et al. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer[J]. Clin Lung Cancer, 2018, 19(1): 58-64. doi: 10.1016/j.cllc.2017.05.015
|
| [1] | WU Yang, LI Tian, SHI Tingting, ZHU Lingling, ZHANG Yani, GUO Peipei, ZHANG Runbing, WANG Shunna, GAO Chun, YU Xiaohui, ZHANG Jiucong. Influencing Factors of Overall Survival of Elderly Patients with Hepatocellular Carcinoma and Construction of Prediction Model of Prognosis Nomogram: A Population-Based Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 756-763. DOI: 10.3971/j.issn.1000-8578.2024.24.0009 |
| [2] | ZHENG Yu, PAN Hongming. Progress of Targeted Therapy and Immunotherapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 234-239. DOI: 10.3971/j.issn.1000-8578.2024.23.1257 |
| [3] | LIU Shanting, QIN Jiali, FAN Jie. Dawn of Advanced Thyroid Cancer Therapy: Targeted Therapy and Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 6-11. DOI: 10.3971/j.issn.1000-8578.2023.22.0869 |
| [4] | HONG Chenchen, YAO Feng. Progress on Tumor Infiltrating Lymphocytes in Immunotherapy and Prognosis Evaluation of Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(11): 1180-1183. DOI: 10.3971/j.issn.1000-8578.2022.22.0332 |
| [5] | TAO Fang, WANG Guowen, HAN Xiuxin, MA Yulin, ZHANG Chao, LI Lili. Prognostic Factors and Comprehensive Treatment of 95 Synovial Sarcoma Patients[J]. Cancer Research on Prevention and Treatment, 2019, 46(6): 519-525. DOI: 10.3971/j.issn.1000-8578.2019.18.1426 |
| [6] | ZENG Fan-yu, TAN Wen-yong, XU Jiao-zhen, WEI Lai, XU Hong-bin, HU De-sheng. Treatment Effect and Prognostic Factors of Postoperative Therapy for 63 Patients with Renal Cell Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(09): 1062-1065. DOI: 10.3971/j.issn.1000-8578.2011.09.023 |
| [7] | ZOU Guo-rong, CAO Xiao-long, ZHANG Chao, XIE Fang-yun, LI Ji-shi, PENG Miao. Multivariate Analysis of Prognostic Factors for Stage T4 Non-metastatic Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2011, 38(09): 1016-1022. DOI: 10.3971/j.issn.1000-8578.2011.09.011 |
| [8] | ZHANG Cui-cui, WANG Jing, LI Kai. Characteristics and Prognostic Analysis of 60 Young Patients with Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 274-277. DOI: 10.3971/j.issn.1000-8578.2011.03.009 |
| [9] | SUN Xi-bin, DUAN Weng-jie, WANG Jing-p ing, et al, . Analysis of Cox Model for Clinical Pathology Factors with Prognosis in Colorecatal Cancer[J]. Cancer Research on Prevention and Treatment, 2001, 28(05): 383-384. DOI: 10.3971/j.issn.1000-8578.970 |
| [10] | Guo Liangjun, . An analysis of the prognostic factors and treatment result for malignant tumours with brain metastasis[J]. Cancer Research on Prevention and Treatment, 1997, 24(4): 235-237. |
| 1. |
杜艳华，白霞. 早期食管癌患者内镜黏膜下剥离术后并发食管狭窄的相关影响因素分析. 实用癌症杂志. 2024(05): 796-799 .
| |
| 2. |
高艳芳，殷云勤，高宇辉. 浅表性食管鳞状细胞癌内镜下非治愈性切除的研究进展. 胃肠病学和肝病学杂志. 2024(09): 1220-1223 .
| |
| 3. |
魏银，陈亚杰，罗丽娜，常钰朋，谭雪娇，陈卫刚，尚国臣，刘浩，田书信. 内镜黏膜下剥离术治疗表浅食管鳞癌和癌前病变的长期疗效. 吉林医学. 2022(03): 607-609 .
| |
| 4. |
张德生，朱晓雷，何剑，郑屹峰，吴晓，储海瑞，郭东闯. 高场强MRI联合血清CYFRA21-1、CA72-4、CA125鉴别食管癌T分期的价值分析. 中华全科医学. 2022(07): 1190-1193 .
| |
| 5. |
刘静，倪牧含，王雷. 食管鳞癌内镜黏膜下剥离术非治愈性切除危险因素分析. 临床军医杂志. 2022(07): 738-740+744 .
| |
| 6. |
潘振国，高成城，谢睿. 早期食管癌和高级别上皮内瘤变行内镜黏膜下剥离术后非治愈性切除的危险因素探讨. 中国内镜杂志. 2021(06): 26-30 .
| |
| 7. |
程卫杰，孙旭锐，袁楚明，吴小珑. 改良ESD在治疗早期食管癌及癌前病变中的应用价值. 临床医学工程. 2021(10): 1309-1310 .
| |
| 8. |
郑荣，王冬梅，张英. 早期食管癌患者行内镜黏膜下剥离术术后并发狭窄的相关危险因素分析. 实用癌症杂志. 2021(11): 1831-1833 .
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: